Alvogen Stock Market Press Releases and Company Profile

View in Other Languages Alvogen在美国首次推出Tamiflu(R)胶囊的仿制药 Alvogen在美國首次推出Tamiflu(R)膠囊的仿製藥 알보젠 타미플루 캡슐 최초 복제약 미국에서 출시 «Альвоген» (Alvogen) начал выпуск первого непатентованного эквивалента капсул Тамифлю (Tamiflu(R)) в Соединенных Штатах Alvogen Launches the First Generic Equivalent to Tamiflu(R) Capsules in the United States 
Alvogen Launches the First Generic Equivalent to Tamiflu(R) Capsules in the United States
Alvogen Launches the First Generic Equivalent to Tamiflu(R) Capsules in the United States

Pine Brook, NJ, Dec 13, 2016 AEST (ABN Newswire) - Alvogen has launched the first generic equivalent to Tamiflu(R) (oseltamivir phosphate) capsules in the United States. Alvogen expects the generic equivalent to Tamiflu(R) capsules to deliver significant savings for patients and health providers of up to $500 million during this upcoming season. The product is available in three strengths (30 mg, 45 mg and 75 mg).

Robert Wessman, Chairman and CEO of Alvogen, commented: "The launch of oseltamivir phosphate is great news for U.S. patients, who will finally have access to a more affordable alternative to Tamiflu. It is also an important milestone for our U.S. business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market."

Alvogen currently has 79 products in development and pending FDA approval for the U.S. market. Annual brand sales for filed products and those under development have current brand sales exceeding $25 billion, according to IMS Health (2015).

In Asia, Alvogen has commercial presence in South-Korea, Taiwan, Japan and China, with regional hubs for R&D and manufacturing in Korea and Taiwan.

In Central & Eastern Europe, Alvogen has commercial presence in Russia, Romania, Hungary, Ukraine, Bulgaria and Poland with a strong portfolio of oncology, rheumatoid arthritis and anemia products and a growing portfolio of over-the-counter products.

A consortium of investors, led by CVC Capital Partners and including Singapore-based investment company Temasek and Vatera Healthcare Partners, acquired a majority stake in Alvogen in June 2015. Alvogen is currently one of the fastest growing pharmaceutical companies in the world, with a commercial presence in 35 countries and a well targeted portfolio of difficult-to-make generics and branded pharmaceuticals.

*Tamiflu is a registered trademark of Hoffman La-Roche Inc. Corporation. Alvogen is not affiliated with Hoffman La-Roche Inc.

Learn more about Alvogen on

About Alvogen

Alvogen KoreaAlvogen is a global, privately owned pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the world.  The company has commercial operations in 35 countries with 2,300 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Taiwan, Romania, Hungary, Ukraine, Japan and China. 


Media Contact
Halldor Kristmannsson
Global Corporate Marketing & Communications
Tel: (+354) 522 2900

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 26) (Last 30 Days: 74) (Since Published: 12145) 

View in Other Languages 3937029345287912522812145 (134879)